Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

  • STATUS
    Recruiting
  • participants needed
    20
  • sponsor
    Fujian Medical University
Send
Updated on 16 February 2024
See if I qualify
stem cell transplantation
cell transplantation
azacitidine
myelodysplastic syndromes
allogeneic hematopoietic stem cell transplant
raeb
myelodysplastic syndrome
cag protocol

Summary

This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .

Details
Condition MDS-EB
Age 65years or below
Treatment Azacitidine, CAG Protocol
Clinical Study IdentifierNCT04216355
SponsorFujian Medical University
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

New Diagnosed advanced myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant is planned
Recipient of an allogeneic hematopoietic stem cell transplantation
Age < 65 years
ECOG performance status 2
Written informed consent
No psychological, familial, social, or geographic reason that would compromise clinical follow up

Exclusion Criteria

Relapsed or refractory advanced MDS
Severe pshyciatric or organic disorder, supposed to be independent from advanced MDS, that would contraindicate treatment
Known allergic or hypersensitivity to azacitidine, aclarubicin or cytarabine or to any of the test compounds, materials
Concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the subject at unacceptable risk
A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

stem cell transplantation
cell transplantation
azacitidine
myelodysplastic syndromes
allogeneic hematopoietic stem cell transplant
raeb
myelodysplastic syndrome
cag protocol

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.